Atlas Trials

Unresectable Rectal Adenocarcinoma

8 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Unresectable Rectal Adenocarcinoma

RecordFirmDate
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (NCT05308446)National Cancer Institute (NCI)2022-07-19
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183)M.D. Anderson Cancer Center2020-12-02
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial (NCT04599140)M.D. Anderson Cancer Center2020-10-14
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (NCT03992456)Academic and Community Cancer Research United2020-04-24
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial (NCT03765736)Academic and Community Cancer Research United2020-04-20
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study (NCT04109924)Roswell Park Cancer Institute2019-12-27
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer (NCT03592641)National Cancer Institute (NCI)2019-07-25
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer (NCT04017650)M.D. Anderson Cancer Center2019-06-14

Track Unresectable Rectal Adenocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.